Breaking News

Yesterday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
RIGL Rigel Pharmaceuticals $2.04 0.025 (1.24%) , GRFS Grifols $19.33 0.26 (1.36%) 11:15 01/23/19 01/23 11:15 01/23/19 11:15 Recommendations	Rigel Pharmaceuticals, Grifols analyst commentary at H.C. Wainwright » H.C. Wainwright boosts… H.C. Wainwright boosts Rigel target to $8 on European partnership. H.C. Wainwright analyst Joseph Pantginis raised his price target for Rigel Pharmaceuticals to $8 from $7.50 saying the company checked an "important box" by signing a partnership for Europe with Grifols (GRFS). The analyst is "pleased" with the Grifols partnership and the terms, "especially the royalty." He's confident Rigel is working on different fronts to boost fostamatinib's clinical and commercial potential outside the U.S. and reiterates a Buy rating on the shares. RIGL Rigel Pharmaceuticals $2.04 0.025 (1.24%) GRFS Grifols $19.33 0.26 (1.36%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
RIGL Rigel Pharmaceuticals $2.02 -0.065 (-3.13%) , GRFS Grifols $19.07 -0.28 (-1.45%) 09:24 01/23/19 01/23 09:24 01/23/19 09:24 Recommendations	Rigel Pharmaceuticals, Grifols analyst commentary at Piper Jaffray » Piper says Grifols deal… Piper says Grifols deal brings Rigel a 'step closer' to positive cash-flow. After Rigel (RIGL) announced an agreement with Grifols (GRFS) to market Tavalisse in Europe and Turkey, Piper Jaffray analyst Christopher Raymond said he believes the $30M upfront payment and $20M on EU approval should enable Rigel to reach cash flow positivity without additional financings. Citing this, and continued traction in the U.S. for Tavalisse, Raymond keeps an Overweight rating on Rigel shares. RIGL Rigel Pharmaceuticals $2.02 -0.065 (-3.13%) GRFS Grifols $19.07 -0.28 (-1.45%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
RIGL Rigel Pharmaceuticals $2.02 -0.065 (-3.13%) , GRFS Grifols $19.07 -0.28 (-1.45%) 07:37 01/23/19 01/23 07:37 01/23/19 07:37 Hot Stocks	Grifols to commercialize Rigel Pharmaceuticals' fostamatinib in Europe » Rigel Pharmaceuticals… Rigel Pharmaceuticals (RIGL) has entered into an exclusive license and supply agreement with Grifols (GRFS) to commercialize fostamatinib disodium hexahydrate in all potential indications in Europe and Turkey. Fostamatinib is commercially available in the U.S. and is the first and only SYK inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The MAA for fostamatinib in chronic ITP is currently under review by the European Medicines Agency, and Rigel anticipates a decision by the end of 2019. Rigel will receive a $30M upfront cash payment, with the potential for $297.5M in payments related to regulatory and commercial milestones, which includes a $20M payment for EMA approval of fostamatinib for the treatment of chronic ITP. Rigel will receive significant stepped double-digit royalty payments based on tiered net sales which may reach 30% of net sales. In return, Grifols receives exclusive rights to fostamatinib in human diseases in Europe and Turkey. Rigel retains the remaining global rights to fostamatinib outside the Grifols territories and those rights previously granted to Kissei Pharmaceuticals. Rigel anticipates a decision from the EMA's Committee on Human Medicinal Products by Q4 and potential European approval by the end of 2019. RIGL Rigel Pharmaceuticals $2.02 -0.065 (-3.13%) GRFS Grifols $19.07 -0.28 (-1.45%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a week ago
GRFS Grifols $18.93 -0.05 (-0.26%) 07:39 01/08/19 01/08 07:39 01/08/19 07:39 Hot Stocks	Grifols receives FDA approval of Erytra Eflexis » Grifols has received U.S.… Grifols has received U.S. FDA approval of Erytra Eflexis, a fully automated, benchtop analyzer. The system performs pretransfusion compatibility testing using DG Gel technology. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
GRFS Grifols $20.40 -0.29 (-1.40%) 07:03 11/23/18 11/23 07:03 11/23/18 07:03 Hot Stocks	Grifols in talks for $5B stake in China's Shanghai RAAS Blood Products » Grifols S.A. disclosed on… Grifols S.A. disclosed on Wednesday that it has started conversations with Shanghai RAAS Blood Products in order to make an investment in the company, which is listed on the Shenzhen Stock Exchange. Grifols would invest in Shanghai RAAS by means of the contribution of its fully owned U.S. subsidiary, Grifols Diagnostic Solutions and its subsidiaries, receiving in exchange Shanghai RAAS newly issued shares. According to the negotiation, the valuation of 100% shares of Grifols Diagnostic Solutions is approximately $5B. Shanghai RAAS is a "market leader in the field of plasma derived medicinal products in China," according to Grifols. Shanghai RAAS has a total of 41 plasma collection centres in China with a fractionation capacity of more than 2M litre. The annual plasma collection in 2017 was approximately of 1.1M litres. Both parties have achieved an initial intent to cooperate. The structure of the transaction and the relevant due diligence are still being discussed. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

GRFS Grifols $20.34 0.91 (4.68%) 05:53 10/30/18 10/30 05:53 10/30/18 05:53 Upgrade	Grifols rating change at Santander » Grifols upgraded to Hold… Grifols upgraded to Hold from Underperform at Santander 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a quarter ago
GRFS Grifols $20.06 0.36 (1.83%) 09:52 10/12/18 10/12 09:52 10/12/18 09:52 Hot Stocks	Grifols' ID CORE XT molecular diagnostic test approved by FDA » Grifols received approval… Grifols received approval from the U.S.FDA for its ID CORE XT molecular diagnostic test for in-vitro diagnostic use in the United States. The blood group genotyping kit has been CE-IVD marked in Europe since 2014. The test will soon be available from Grifols as a kit to be used in the laboratory and as a send-out testing service from the Grifols Immunohematology Center in San Marcos, Texas. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GRFS Grifols $18.70 -1.45 (-7.20%) 09:33 10/11/18 10/11 09:33 10/11/18 09:33 Upgrade	Grifols rating change at Berenberg » Grifols upgraded to Buy… Grifols upgraded to Buy from Hold at Berenberg 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GRFS Grifols $20.14 -0.99 (-4.69%) 13:44 10/03/18 10/03 13:44 10/03/18 13:44 Hot Stocks	Grifols 'strongly disagrees' with conclusions of UBS report » In a regulatory filing,… In a regulatory filing, Grifols stated that the company "strongly disagrees" with the conclusions of a UBS report issued today on the potential impact of inhibitors of the neonatal receptor of the C fragment to Grifols' immunoglobulin business. Grifols said: "The report is based solely on preliminary clinical studies with a very limited number of patients and therefore results are not conclusive with regard to safety and efficacy of the products to treat some autoimmune diseases. The product, to be approved after phase III trials, must prove equal or superior efficacy to immunoglobulin. Even if safety and efficacy were demonstrated, FcRn would only impact a limited number of diseases and patients. For that reason the company believes the potential impact on its business would be minimal. Demand for immunoglobulin well exceeds supply. The company continues innovating and developing new opportunities for the use of immunoglobulins and guaranteeing access for patients to the product by investing in plasma supply and new production facilities." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GRFS Grifols $19.72 -1.41 (-6.67%) 11:45 10/03/18 10/03 11:45 10/03/18 11:45 Periodicals	Grifols says it disagrees with UBS downgrade report, Bloomberg reports » Bloomberg cites a… Bloomberg cites a statement issued by the company to the CNMV, the National Securities Market Commission of the Spanish government. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial